HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

In Brief: Revlon

This article was originally published in The Rose Sheet

Executive Summary

Revlon: Begins initial public offering of 7.5 mil. shares of Class A common stock at $24 per share on Feb. 29, the firm said. The stock closed the first day at 27-5/8, trading as high as 29-5/8. Six million of the 7.5 mil. shares will be offered in the U.S. and Canada. The offering is being underwritten by Merrill Lynch and CS First Boston, who have an option to purchase up to 1.1 mil. shares for over-allotments. If all over-allotments are excercised, the company stands to gross $206.4 mil. before underwriting discounts and offering expenses. The offering price is higher than the initial price range of $19-$22 disclosed in an amended prospectus for the company's IPO filed Feb. 5 ("The Rose Sheet" Feb. 12, p. 2). Revlon first announced it would go public Nov. 17...

Latest Headlines
See All
UsernamePublicRestriction

Register

RS002569

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel